- Home
- DARE vs SST Comparison
DARE vs SST Comparison
Compare DARE & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- SST
- Stock Information
- Founded
- DARE 2015
- SST 2013
- Country
- DARE United States
- SST United States
- Employees
- DARE N/A
- SST N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- SST Diversified Commercial Services
- Sector
- DARE Health Care
- SST Consumer Discretionary
- Exchange
- DARE Nasdaq
- SST Nasdaq
- Market Cap
- DARE 26.3M
- SST 23.3M
- IPO Year
- DARE N/A
- SST N/A
- Fundamental
- Price
- DARE $2.38
- SST $6.34
- Analyst Decision
- DARE Strong Buy
- SST Strong Buy
- Analyst Count
- DARE 3
- SST 1
- Target Price
- DARE $12.50
- SST $500.00
- AVG Volume (30 Days)
- DARE 40.1K
- SST 305.7K
- Earning Date
- DARE 08-11-2025
- SST 08-07-2025
- Dividend Yield
- DARE N/A
- SST N/A
- EPS Growth
- DARE N/A
- SST N/A
- EPS
- DARE N/A
- SST N/A
- Revenue
- DARE $25,909.00
- SST $333,521,000.00
- Revenue This Year
- DARE $99,756.91
- SST N/A
- Revenue Next Year
- DARE $119.77
- SST $8.39
- P/E Ratio
- DARE N/A
- SST N/A
- Revenue Growth
- DARE N/A
- SST N/A
- 52 Week Low
- DARE $2.35
- SST $2.90
- 52 Week High
- DARE $4.60
- SST $15.70
- Technical
- Relative Strength Index (RSI)
- DARE 34.73
- SST 52.72
- Support Level
- DARE $2.56
- SST $3.65
- Resistance Level
- DARE $2.95
- SST $15.00
- Average True Range (ATR)
- DARE 0.12
- SST 2.04
- MACD
- DARE -0.05
- SST 0.25
- Stochastic Oscillator
- DARE 8.45
- SST 25.09
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.